Explore AstraZeneca's recent Form 6-K detailing CEO Pascal Soriot's transfer of 136,537 shares as a gift. Discover the implications for shareholder dynamics and regulatory compliance.
Explore Gilead Sciences' Q3 2025 financial performance with key insights on revenue, EPS, and debt challenges. Recommendations indicate a cautious hold for investors.
Explore AstraZeneca's Q3 2025 financial performance highlighting an 11% revenue growth, improved margins, and a strong pipeline. A must-read for investors!
Discover AstraZeneca PLC's latest 6-K report detailing voting rights, share capital, and compliance insights. Essential for investors and stakeholders in the biopharmaceutical sector.
AstraZeneca's 6-K filing details the approval of new articles of association, enhancing capital access. Key voting results and future trading updates included.
Discover AstraZeneca's latest Form 6-K report on Euan Ashley's director appointment at DexCom. Key insights on governance and compliance included.
AstraZeneca's SEC Form 6-K reveals promising results for Datroway in metastatic triple-negative breast cancer, showing significant survival improvements in patients not eligible for immunotherapy.
Discover AstraZeneca PLC's latest financial insights, including voting rights and regulatory compliance under Form 20-F. Essential for investors and stakeholders.
Discover AstraZeneca's Enhertu's promising trial results for HER2-positive early breast cancer, showcasing significant survival improvements and plans for regulatory approval.
Discover AstraZeneca PLC's latest Form 6-K detailing voting rights and share capital as of August 31, 2025. Key info for shareholders on compliance and transparency.
AstraZeneca PLC's August 2025 report corrects a TR-1 notification error. Shareholders should refer to the proper TR-1 from 21 August. Find details on their investor relations site.
Explore AstraZeneca PLC's latest Form 6-K, filed on August 1, 2025, detailing 1.55B voting rights and compliance with UK regulations vital for shareholders.